<DOC>
	<DOCNO>NCT01604057</DOCNO>
	<brief_summary>This study conduct evaluate effect treatment serum P1NP level , biomarker bone formation postmenopausal woman low bone mass .</brief_summary>
	<brief_title>Study Evaluate Effect Intranasal Teriparatide Serum P1NP , Biomarker Bone Formation , Postmenopausal Women With Low Bone Mass</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Postmenopausal Females Age ≥ 45 year . Weight &gt; 45 kg &lt; 90 kg Normal nasal examination baseline . Low bone mass lumbar spine , total hip femoral neck ( BMD Tscore ≤ 1.5 low ) recent ( within 5 year baseline ) history fragility fracture ( exclude fracture hand , foot , face and/or skull ) Tscore 1.0 low lumbar spine , total hip femoral neck Serious Medical Condition History diseases affect bone metabolism postmenopausal osteoporosis Paget 's disease , secondary cause osteoporosis , hypoparathyroidism , hyperparathyroidism Have history cancer within past 5 year , except basal cell carcinoma Have hypocalcemia hypercalcemia cause recent history kidney stone preexist hypercalciuria ; Have use mostly commonly prescribe osteoporosis medication within 3 month start investigational product , 1 month time within 6 month prior start investigational product</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>